In this study, we have taken advantage of this new GLUT1 candidate inhibitor along with molecular approach to examine the roles of GLUT1 in glycolysis regulation and growth of ovarian cancer cell lines and ovarian cancer patient-derived xenografts (PDXs). The gene discussed is SLC2A1; the disease is ovarian carcinoma.